The collaboration aims to help IBD-focused biopharma sponsors overcome critical challenges in therapy development by leveraging advanced AI and machine learning to design more flexible, patient-centric trials with a higher probability of success. It will further accelerate research and the development of novel therapies through potential joint publications and the sharing of knowledge with the broader IBD ecosystem.
"We are committed to breaking down barriers in clinical development to drive transformative progress for the IBD community," said Angela Dobes, Senior Vice President of IBD Plexus at the Crohn's & Colitis Foundation. "By leveraging the unparalleled breadth of IBD Plexus' data alongside PhaseV's cutting-edge AI and machine learning platform, we aim to transform trial design and patient recruitment, expediting timelines and advancing more tailored solutions to improve outcomes for IBD patients."
Designing clinical trials for more effective IBD treatments is an ongoing challenge due to significant heterogeneity in disease presentation, progression, and individual treatment response. Factors such as subtype, location, severity, immune response, and genetic background create complexity that traditional, fixed trial designs struggle to address. Moreover, relying on assumptions made at the outset of a trial can lead to suboptimal outcomes, missed signals, high failure rates and delays in bringing effective treatments to market.
The partnership seeks to bridge these gaps by leveraging IBD Plexus' extensive datasets and applying PhaseV's AI/ML technology. This data-driven approach empowers clinical teams to continuously learn from accumulating data, enabling sponsors to adapt trial designs in real time. This approach addresses patient heterogeneity and inefficient clinical development processes while facilitating more personalized treatment approaches. In addition to adaptive trial design, PhaseV's causal disease modeling also helps sponsors uncover meaningful biomarker-outcome relationships.
"IBD is a complex disease that demands new approaches to research and development," said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. "We are proud to partner with the Crohn's & Colitis Foundation, reflecting our commitment to addressing the most pressing challenges in IBD therapy development to deliver more effective treatments for patients. Together, we aim to create a more efficient path toward safe and effective IBD treatments."
About PhaseV
PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions.
Augmented by a robust data lake that integrates high-quality patient-level data, clinical trial results, real-world evidence, and peer-reviewed insights, the platform has demonstrated a reduction in trial costs by 50%, a decrease in enrollment size and trial duration by 40%, and more than 30% increase in the likelihood of trial success.
To date, the company has delivered results for more than 30 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others. Learn more at www.PhaseVTrials.com and follow us on LinkedIn.
About the Crohn's & Colitis Foundation
The Crohn's & Colitis Foundation is the leading nonprofit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn's disease and ulcerative colitis and improving the quality of life for the millions of Americans living with IBD. The Foundation's work is dramatically accelerating the research process, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public. For more information, visit http://www.crohnscolitisfoundation.org.
Media Contact:
Ellie Hanson
FINN Partners for PhaseV
[email protected]
929-588-2008
Photo: https://mma.prnewswire.com/media/2697726/PhaseV_CCF_Collab.jpg
Logo: https://mma.prnewswire.com/media/2267452/PhaseV_logo.jpg
SOURCE PhaseV; Crohn's & Colitis Foundation
Share this article